Casdin Capital Portfolio

Casdin Capital 13F filer (CIK 0001534261).

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 47 positions · Total reported value $2.29B · Top-10 concentration 76.4% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 26.5% · 6 new · 5 cut · 2 exited

Active Share (vs S&P 500): 99.7% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Casdin Capital disclosed 47 equity positions with a combined reported value of $2.29B. The filing implies a focused portfolio: its ten largest positions account for 76.4% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were RVMD ($529.02M), RLAY ($289.44M), WGS ($268.03M). By sector, the heaviest allocations are Health Care 91.4%, Industrials 7.1%. Versus the prior quarter, allocation shifted toward Technology (+1.5pp), Industrials (+1.4pp) and away from Health Care (-2.9pp).

Versus the prior quarter, Casdin Capital opened 6 new positions, trimmed 5 and fully exited 2, a turnover rate of 26.5% of positions. The portfolio's overlap with the prior quarter was 84% of names.

The largest new positions opened in Q3 2026 were TEM ($34.69M), ORIC ($16.84M), BIIB ($11.29M).

Of the 2 positions fully exited versus the prior quarter, the largest were SION ($17.60M), IRON ($4.75M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • TEM TEMPUS AI INC · $34.69M
  • ORIC ORIC PHARMACEUTICALS INC · $16.84M
  • BIIB BIOGEN INC · $11.29M
  • EWTX EDGEWISE THERAPEUTICS INC · $10.76M
  • BNTX BIONTECH SE · $8.36M
  • RAPP RAPPORT THERAPEUTICS INC · $6.72M

Fully Exited (vs previous quarter)

  • SION SIONNA THERAPEUTICS INC · prev qtr: $17.60M
  • IRON DISC MEDICINE INC · prev qtr: $4.75M

Insider Transactions (Form 4)

Latest Casdin Capital buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Casdin Capital is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 47 US equity positions with a combined value of $2.29B. HoldingsHub carries 44 quarters of its filings (Q4 2015–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-110894 (status: Approved), registered 2017-07-31
  • Regulatory AUM (Form ADV): $2.87B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 5 private funds, of which 2 hedge funds

Portfolio Structure

  • 47 positions · $2.29B reported value (Q3 2026)
  • Top 10 holdings = 76.4% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 23.1%
  • Average position size: $48.67M

Sector Tilt

  • Health Care 91.4%
  • Industrials 7.1%
  • Information Technology 1.5%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 6 new, 8 added, 5 reduced, 2 exited
  • 28 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: Casdin Capital increased exposure to biotech/healthcare (e.g., GRAL, NGNE, SRRK) while trimming some existing positions (BLFS), suggesting a bullish view on innovative therapeutics but selective profit-taking. 2. Key moves: - Added: GRAL (+41.7% shares), NGNE (+2.6% shares), SRRK (+27.8% shares). - Reduced: BLFS (-3.3% shares). 3. Portfolio structure: Active, concentrated (47 positions), heavily biased toward Health Care (9/10 top holdings), with moderate risk appetite (high-conviction biotech bets). 4. Per-holding one-liner: - RVMD: Revolution Medicines (cancer therapeutics). - RLAY: Relay Therapeutics (drug discovery). - WGS: Genedx Holdings (genetic testing). - BLFS: Biolife Solutions (cell preservation). - ILMN: Illumina (genomic sequencing). - GRAL: Grail (early cancer detection). - TXG: 10x Genomics (genomics tools). - LAB: Standard Biota (synthetic biology). - NGNE: Neurogene (gene therapy). - SRRK: Scholar Rock (muscle disease drugs). 5. Style summary: Biotech-focused active manager selectively increasing exposure to high-growth therapeutic platforms while trimming select positions.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 10:09

Sector Allocation

Health Care 91.4%
Technology 1.5%
Other 0.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 2.58M $529.02M 23.12%
23.12%
Hold
2 16.04M $289.44M 12.65%
12.65%
Hold
3 3.71M $268.03M 11.72%
11.72%
Hold
4 4.50M $174.82M 7.64%
7.64%
Reduce
5 530.00K $145.05M 6.34%
6.34%
Hold
6 680.00K $95.28M 4.17%
4.17%
Add
7 1.05M $94.88M 4.15%
4.15%
Hold
8 88.78M $65.75M 2.87%
2.87%
Hold
9 1.59M $44.10M 1.93%
1.93%
Add
10 850.00K $41.07M 1.79%
1.79%
Add
11 2.30M $37.44M 1.64%
1.64%
Reduce
12 1.50M $36.67M 1.60%
1.60%
Add
13 423.60K $34.69M 1.52%
1.52%
New
14 1.82M $33.16M 1.45%
1.45%
Add
15 185.00K $33.00M 1.44%
1.44%
Hold
16 1.03M $32.21M 1.41%
1.41%
Reduce
17 120.00K $29.61M 1.29%
1.29%
Add
18 1.25M $25.84M 1.13%
1.13%
Reduce
19 800.00K $23.83M 1.04%
1.04%
Add
20 843.86K $22.94M 1.00%
1.00%
Hold
21 553.27K $21.65M 0.95%
0.95%
Hold
22 645.69K $20.85M 0.91%
0.91%
Hold
23 1.25M $20.00M 0.87%
0.87%
Hold
24 3.90M $18.99M 0.83%
0.83%
Add
25 1.55M $17.20M 0.75%
0.75%
Hold
26 1.25M $16.84M 0.74%
0.74%
New
27 75.00K $14.44M 0.63%
0.63%
Hold
28 276.31K $12.72M 0.56%
0.56%
Hold
29 50.00K $11.65M 0.51%
0.51%
Hold
30 50.00K $11.29M 0.49%
0.49%
New
31 265.00K $10.76M 0.47%
0.47%
New
32 973.26K $10.48M 0.46%
0.46%
Hold
33 3.17M $9.68M 0.42%
0.42%
Hold
34 85.00K $8.36M 0.36%
0.36%
New
35 200.00K $6.72M 0.29%
0.29%
New
36 355.00K $4.28M 0.19%
0.19%
Hold
37 150.00K $3.62M 0.16%
0.16%
Hold
38 1.23M $2.10M 0.09%
0.09%
Hold
39 148.33K $1.99M 0.09%
0.09%
Hold
40 723.77K $1.72M 0.07%
0.07%
Hold
41 282.31K $1.16M 0.05%
0.05%
Hold
42 445.00K $1.14M 0.05%
0.05%
Hold
43 86.01K $1.03M 0.04%
0.04%
Reduce
44 50.00K $737.50K 0.03%
0.03%
Hold
45 165.32K $682.78K 0.03%
0.03%
Hold
46 36.49K $468.20K 0.02%
0.02%
Hold
47 361.97K $218.48K 0.01%
0.01%
Hold

FAQ

What did Casdin Capital buy in 2026-Q3?

In its 2026-Q3 13F filing, Casdin Capital reported 47 equity positions worth $2.29B in aggregate; its largest disclosed positions were RVMD ($529.02M), RLAY ($289.44M), WGS ($268.03M).

How large is Casdin Capital's portfolio?

Casdin Capital reported $2.29B of long equity holdings across 47 positions as of 2026-Q3. Top-10 holdings account for 76.4% of reported value.

What is Casdin Capital's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/casdin/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →